EP3558328A4 - Compositions and methods for reprogramming somatic cells into induced vasculogenic cells - Google Patents

Compositions and methods for reprogramming somatic cells into induced vasculogenic cells Download PDF

Info

Publication number
EP3558328A4
EP3558328A4 EP17882356.3A EP17882356A EP3558328A4 EP 3558328 A4 EP3558328 A4 EP 3558328A4 EP 17882356 A EP17882356 A EP 17882356A EP 3558328 A4 EP3558328 A4 EP 3558328A4
Authority
EP
European Patent Office
Prior art keywords
cells
induced
compositions
methods
vasculogenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP17882356.3A
Other languages
German (de)
French (fr)
Other versions
EP3558328A1 (en
Inventor
Chandan Sen
Ly James Lee
Daniel GALLEGO-PEREZ
Durba PAL
Subhadip GHATAK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ohio State Innovation Foundation
Original Assignee
Ohio State Innovation Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ohio State Innovation Foundation filed Critical Ohio State Innovation Foundation
Publication of EP3558328A1 publication Critical patent/EP3558328A1/en
Publication of EP3558328A4 publication Critical patent/EP3558328A4/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/65—MicroRNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/09—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from epidermal cells, from skin cells, from oral mucosa cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1307—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from adult fibroblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1323—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from skeletal muscle cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2529/00—Culture process characterised by the use of electromagnetic stimulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
EP17882356.3A 2016-12-22 2017-12-20 Compositions and methods for reprogramming somatic cells into induced vasculogenic cells Pending EP3558328A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662438260P 2016-12-22 2016-12-22
US201762530132P 2017-07-08 2017-07-08
PCT/US2017/067631 WO2018119091A1 (en) 2016-12-22 2017-12-20 Compositions and methods for reprogramming somatic cells into induced vasculogenic cells

Publications (2)

Publication Number Publication Date
EP3558328A1 EP3558328A1 (en) 2019-10-30
EP3558328A4 true EP3558328A4 (en) 2020-08-26

Family

ID=62628033

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17882356.3A Pending EP3558328A4 (en) 2016-12-22 2017-12-20 Compositions and methods for reprogramming somatic cells into induced vasculogenic cells

Country Status (9)

Country Link
US (1) US11578107B2 (en)
EP (1) EP3558328A4 (en)
JP (1) JP2020511116A (en)
KR (1) KR20190096414A (en)
CN (1) CN110753758A (en)
AU (2) AU2017379880A1 (en)
BR (1) BR112019012997A2 (en)
CA (1) CA3046982A1 (en)
WO (1) WO2018119091A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130123647A1 (en) 2011-05-03 2013-05-16 The Research Foundation Of State University Of New York Methods Useful in Optimizing the Treatment of Neuropathies and Targeting Tissues with Cosmetic Botulinum Injections
US11491483B2 (en) 2018-02-15 2022-11-08 Ohio State Innovation Foundation Microfluidic devices and methods for high throughput electroporation
JP2021531805A (en) * 2018-08-01 2021-11-25 オハイオ・ステイト・イノベーション・ファウンデーション Compositions and Methods for Reprogramming Skin into Insulin-Producing Tissues
MX2022000074A (en) * 2019-07-02 2022-04-06 Ohio State Innovation Foundation Neurodegenerative disease therapies utilizing the skin-brain axis.
AU2020351219A1 (en) * 2019-09-20 2022-03-31 The Trustees Of Indiana University Vasculogenic fibroblasts
CA3173745A1 (en) * 2020-02-27 2021-09-02 The Trustees Of Indiana University Cell-targeted nanoparticles to inhibit rna cargo
CA3174443A1 (en) * 2020-03-04 2021-09-10 The Trustees Of Indiana University Methods to re-engage a fetal wound healing pathway for adult skin repair
WO2021188894A2 (en) * 2020-03-20 2021-09-23 University Of Massachusetts Micrornas for prevention of clinical venous thromboembolic disease
WO2021253007A1 (en) * 2020-06-12 2021-12-16 Emory University Direct in vivo reprogramming using transcription factor etv2 gene for endothelial cell and vessel formation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013181326A1 (en) * 2012-05-30 2013-12-05 Cornell University Generation of functional and durable endothelial cells from human amniotic fluid-derived cells
WO2015133792A1 (en) * 2014-03-03 2015-09-11 국립대학법인 울산과학기술대학교 산학협력단 Composition for inducing direct transdifferentiation of somatic cell into vascular progenitor cell, and use thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2533701A1 (en) 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas
US8969314B2 (en) 2003-07-31 2015-03-03 Regulus Therapeutics, Inc. Methods for use in modulating miR-122a
US20050142581A1 (en) 2003-09-04 2005-06-30 Griffey Richard H. Microrna as ligands and target molecules
US7579451B2 (en) 2004-07-21 2009-08-25 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising a modified or non-natural nucleobase
US20080213891A1 (en) 2004-07-21 2008-09-04 Alnylam Pharmaceuticals, Inc. RNAi Agents Comprising Universal Nucleobases
CA2574603C (en) 2004-08-04 2014-11-04 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase
WO2007021896A2 (en) 2005-08-10 2007-02-22 Alnylam Pharmaceuticals, Inc. Chemically modified oligonucleotides for use in modulating micro rna and uses thereof
US20070213292A1 (en) 2005-08-10 2007-09-13 The Rockefeller University Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
EP2338992A3 (en) 2005-08-29 2011-10-12 Regulus Therapeutics, Inc Antisense compounds having enhanced anti-microRNA activity
EP1984499B1 (en) 2006-01-27 2015-05-27 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for the use in modulation of micrornas
KR101407707B1 (en) 2006-04-03 2014-06-19 산타리스 팔마 에이/에스 Pharmaceuical composition comprising anti-mirna antisense oligonucleotides
WO2008046911A2 (en) 2006-10-20 2008-04-24 Exiqon A/S Novel human micrornas associated with cancer
US20090137504A1 (en) 2006-12-21 2009-05-28 Soren Morgenthaler Echwald Microrna target site blocking oligos and uses thereof
US9816086B2 (en) * 2010-07-06 2017-11-14 The Ohio State University Dose and location controlled drug/gene/particle delivery to individual cells by nanoelectroporation
JP5897002B2 (en) * 2010-07-07 2016-04-13 セルラー ダイナミクス インターナショナル， インコーポレイテッド Endothelial cell production by programming
JP2015109833A (en) * 2013-11-08 2015-06-18 学校法人慶應義塾 Method of producing endothelial cell from fibroblast
KR101702629B1 (en) * 2014-03-03 2017-02-06 울산과학기술원 Composition for inducing direct conversion of somatic cell into vascular progenitor cell and use the same
US10023842B2 (en) 2014-04-29 2018-07-17 Emory University Endothelial and endothelial like cells produced from fibroblasts and uses related thereto

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013181326A1 (en) * 2012-05-30 2013-12-05 Cornell University Generation of functional and durable endothelial cells from human amniotic fluid-derived cells
WO2015133792A1 (en) * 2014-03-03 2015-09-11 국립대학법인 울산과학기술대학교 산학협력단 Composition for inducing direct transdifferentiation of somatic cell into vascular progenitor cell, and use thereof

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DANIEL GALLEGO-PEREZ ET AL: "Supplementary Information: Topical tissue nano-transfection mediates non-viral stroma reprogramming and rescue", NATURE NANOTECHNOLOGY, vol. 12, no. 10, 7 August 2017 (2017-08-07), London, pages 974 - 979, XP055714984, ISSN: 1748-3387, DOI: 10.1038/nnano.2017.134 *
DANIEL GALLEGO-PEREZ ET AL: "Topical tissue nano-transfection mediates non-viral stroma reprogramming and rescue | Nature Nanotechnology", NATURE NANOTECHNOLOGY, vol. 12, 7 August 2017 (2017-08-07) - 7 August 2017 (2017-08-07), pages 974 - 979, XP055714980, Retrieved from the Internet <URL:https://www.nature.com/articles/nnano.2017.134> [retrieved on 20200715] *
DANIEL GALLEGO-PEREZ: "Supplementary Material for: Deterministic Transfection Drives Efficient Nonviral Reprogramming and Uncovers Reprogramming Barriers", NANOMEDICINE: NANOTECHNOLOGY, BIOLOGY AND MEDICINE, 19 December 2015 (2015-12-19), XP055715008, Retrieved from the Internet <URL:https://www.sciencedirect.com/science/article/pii/S154996341500595X?via%3Dihub> [retrieved on 20200715] *
GALLEGO-PEREZ DANIEL ET AL: "Deterministic transfection drives efficient nonviral reprogramming and uncovers reprogramming barriers", NANOMEDICINE: NANOTECHNOLOGY, BIOLOGY AND MEDICINE, vol. 12, no. 2, 19 December 2015 (2015-12-19), pages 399 - 409, XP029459510, ISSN: 1549-9634, DOI: 10.1016/J.NANO.2015.11.015 *
SARAH DE VAL ET AL: "Combinatorial Regulation of Endothelial Gene Expression by Ets and Forkhead Transcription Factors", CELL, vol. 135, no. 6, 1 December 2008 (2008-12-01), AMSTERDAM, NL, pages 1053 - 1064, XP055713594, ISSN: 0092-8674, DOI: 10.1016/j.cell.2008.10.049 *
See also references of WO2018119091A1 *

Also Published As

Publication number Publication date
BR112019012997A2 (en) 2019-12-10
JP2020511116A (en) 2020-04-16
AU2017379880A1 (en) 2019-07-04
EP3558328A1 (en) 2019-10-30
WO2018119091A1 (en) 2018-06-28
KR20190096414A (en) 2019-08-19
CN110753758A (en) 2020-02-04
US11578107B2 (en) 2023-02-14
CA3046982A1 (en) 2018-06-28
AU2024201552A1 (en) 2024-05-02
US20200115425A1 (en) 2020-04-16

Similar Documents

Publication Publication Date Title
EP3523419A4 (en) Compositions and methods for maintaining cell viability
EP3558328A4 (en) Compositions and methods for reprogramming somatic cells into induced vasculogenic cells
EP3532613A4 (en) Methods and compositions for rna mapping
EP3317405A4 (en) Compositions and methods for reprograming non-neuronal cells into neuron-like cells
EP3362104A4 (en) Methods and compositions utilizing cpf1 for rna-guided gene editing
EP3328377A4 (en) Compositions and methods for immuno-oncology therapies
EP3212225A4 (en) Methods and compositions for modified t cells
EP3114214A4 (en) Improved reprogramming methods and cell culture platforms
EP3471772A4 (en) Compositions and methods for the depletion of cells
EP3223856A4 (en) Methods and compositions for natural killer cells
EP3490366A4 (en) Methods and compositions for gene expression in plants
EP3288387A4 (en) Microbial compositions and methods for bioprotection
EP3215139A4 (en) Compositions and methods for improved car-t cell therapies
EP3428265A4 (en) Cell culture device and cell culture method
EP3503879A4 (en) Compositions and methods thereof
EP3384038A4 (en) Methods and compositions for reprogramming cells
EP3436083A4 (en) Novel compositions and methods
EP3442543A4 (en) Compositions and methods for neuralgenesis
EP3245303A4 (en) Age-modified cells and methods for making age-modified cells
EP3150704A4 (en) Culture method and cell mass
EP3521419A4 (en) Method for producing somatic cell, somatic cell, and composition
EP3272855A4 (en) Liver cells and liver non-parenchymal cells, and methods for preparation thereof
WO2017107898A9 (en) Compositions and methods for gene editing
EP3534911A4 (en) Methods and compositions for cellular reprogramming
EP3452580A4 (en) Compositions and methods for improved nk cell therapies

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190607

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20200727

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 35/44 20150101ALI20200721BHEP

Ipc: A61K 35/36 20150101AFI20200721BHEP

Ipc: C12N 15/85 20060101ALI20200721BHEP

Ipc: C12N 5/071 20100101ALI20200721BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20210701

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS